A review on the role of gut microbiota in immune checkpoint blockade therapy for cancer

Kim, Esther; Ahn, Hyeok; Park, Hansoo

doi:10.1007/s00335-021-09867-3

Cited by 21 publications

(12 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this interesting report, fecal samples from patients responding to ICIS showed higher taxa richness compared to fecal samples of non-responders, suggesting that human microbiota could have a notable impact on responses to immunotherapy in HCC patients (90). Despite the application of gut microbiota in modulating response to immunotherapy remains far from clinical practice, the landmark role of gut microbiota in modulating innate and adaptive immunity supports makes this research avenue particularly promising (91)(92)(93)(94)(95)(96).…”

Section: Gut Microbiotamentioning

confidence: 89%

Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?

et al. 2021

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) remains the sixth most commonly diagnosed malignancy worldwide, still representing an important cause of cancer-related death. Over the next few years, novel systemic treatment options have emerged. Among these, immune checkpoint inhibitors (ICIs) have been widely evaluated and are under assessment, as monotherapy or in combination with other anticancer agents in treatment-naïve and previously treated patients. In particular, the approval of the PD-L1 inhibitor atezolizumab plus the antiangiogenic agent bevacizumab as front-line treatment for advanced HCC has led to the adoption of this combination in this setting, and the IMbrave 150 phase III trial has established a novel standard of care. However, several questions remain unanswered, including the identification of reliable predictors of response to ICIs in HCC patients. In the current paper, we will provide an updated overview of potentially useful predictive biomarkers of response to immunotherapy in advanced HCC. A literature search was conducted in September 2021 of Pubmed/Medline, Cochrane library and Scopus databases.

show abstract

Section: Gut Microbiotamentioning

confidence: 89%

Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?

et al. 2021

View full text Add to dashboard Cite

show abstract

“…To date, few studies have examined the impact of the gut microbiome on the clinical response of ICIs, namely progression-free survival (PFS), overall survival (OS) and irAEs, although several studies have suggested a critical role for the gut microbiome in mediating responses to immunotherapies. Previous reviews have included both animal models and clinical studies and have attempted to elucidate the underlying mechanisms of dysbiosis of gut microbiota in immune responses [ 15 , 17 ]. Our current review, therefore, assesses the association between the gut microbiome and the therapeutic benefits of ICIs in metastatic advanced cancer patients.…”

Section: Introductionmentioning

confidence: 99%

The Gut Microbiome and Cancer Immunotherapy: Can We Use the Gut Microbiome as a Predictive Biomarker for Clinical Response in Cancer Immunotherapy?

Boyle

Pavlakis

et al. 2021

Cancers

View full text Add to dashboard Cite

Background: Emerging evidence suggests that gut microbiota influences the clinical response to immunotherapy. This review of clinical studies examines the relationship between gut microbiota and immunotherapy outcomes. Method: A literature search was conducted in electronic databases Medline, PubMed and ScienceDirect, with searches for “cancer” and “immunotherapy/immune checkpoint inhibitor” and “microbiome/microbiota” and/or “fecal microbiome transplant FMT”. The relevant literature was selected for this article. Results: Ten studies examined patients diagnosed with advanced metastatic melanoma (n = 6), hepatocellular carcinoma (HCC) (n = 2), non-small cell lung carcinoma (NSCLC) (n = 1) and one study examined combination both NSCLC and renal cell carcinoma (RCC) (n = 1). These studies consistently reported that the gut microbiome profile prior to administering immune checkpoint inhibitors (ICIs) was related to clinical response as measured by progression-free survival (PFS) and overall survival (OS). Two studies reported that a low abundance of Bacteroidetes was associated with colitis. Two studies showed that patients with anti-PD-1 refractory metastatic melanoma experienced improved response rates and no added toxicity when receiving fecal microbiota transplant (FMT) from patients with anti-PD-1 responsive disease. Conclusions: Overall, significant differences in the diversity and composition of the gut microbiome were identified in ICIs responders and non-responders. Our findings provide new insights into the value of assessing the gut microbiome in immunotherapy. Further robust randomized controlled trials (RCTs) examining the modulatory effects of the gut microbiome and FMT on ICIs in patients not responding to immunotherapy are warranted.

show abstract

“…Barnesiella was reported to remove pathogenic bacterium, to eliminate the colonization of Enterococcus that are resistant to vancomycin and to restrain antibiotic-resistant bacteria from spreading [ 153 ]. It could improve anticancer compounds such as cyclophosphamide [ 154 ]. The reduction of Barnesiella was probably related to the pathogenesis of IBD.…”

Section: Food Colorantsmentioning

confidence: 99%

Food Additives Associated with Gut Microbiota Alterations in Inflammatory Bowel Disease: Friends or Enemies?

et al. 2022

View full text Add to dashboard Cite

During the 21st century, the incidence and prevalence of inflammatory bowel disease (IBD) is rising globally. Despite the pathogenesis of IBD remaining largely unclear, the interactions between environmental exposure, host genetics and immune response contribute to the occurrence and development of this disease. Growing evidence implicates that food additives might be closely related to IBD, but the involved molecular mechanisms are still poorly understood. Food additives may be categorized as distinct types in accordance with their function and property, including artificial sweeteners, preservatives, food colorant, emulsifiers, stabilizers, thickeners and so on. Various kinds of food additives play a role in modifying the interaction between gut microbiota and intestinal inflammation. Therefore, this review comprehensively synthesizes the current evidence on the interplay between different food additives and gut microbiome alterations, and further elucidates the potential mechanisms of food additives–associated microbiota changes involved in IBD.

show abstract

A review on the role of gut microbiota in immune checkpoint blockade therapy for cancer

Cited by 21 publications

References 20 publications

Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?

Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?

The Gut Microbiome and Cancer Immunotherapy: Can We Use the Gut Microbiome as a Predictive Biomarker for Clinical Response in Cancer Immunotherapy?

Food Additives Associated with Gut Microbiota Alterations in Inflammatory Bowel Disease: Friends or Enemies?

Contact Info

Product

Resources

About